Results 151 to 160 of about 17,108 (194)
, 2002 Some of the next articles are maybe not open access.
Related searches:
Related searches:
ALZA: An enterprise in biomedical innovation
Technovation, 1981Abstract Pharmaceutical innovators confront increasingly severe problems: prolonged lead times for product development and approval; soaring costs; and constraining factors implicit in the chemical approach to inventing or improving drugs. To avoid the problems of the chemical approach, which has previously dominated pharmaceutical R&D, the ALZA ...
openaire +1 more source
Alza Corporation: An Illustration of Form Over Substance
SSRN Electronic Journal, 2006Before merging with Johnson & Johnson in 2001, ALZA Pharmaceuticals Corporation was on the cutting edge of both drug delivery systems and creative financial arrangements. This paper explains the creation of two spin-off corporations by ALZA for the purpose of funding research and development (R&D) activities to be carried out primarily by and for the ...
Timothy L. McCoy, Margaret A. Hoskins
openaire +1 more source
A broader horizon of Alzheimer pathogenesis: ALZAS — an early serum biomarker?
Journal of Neural Transmission Supplementum, 2002Recently, a novel risk gene protein expressed in elderly patients with the diagnosis of Alzheimer disease (AD) was discovered on chromosome 21 within the APP (amyloid precursor protein) region. This 79 amino acid protein, ALZAS (Alzheimer Associated Protein) contains the beta-amyloid peptide 1-42 fragment, the APP transmembrane signal, and a unique 12 ...
E, Kienzl +4 more
exaly +3 more sources
IDrugs : the investigational drugs journal, 2005
Alza is developing both transdermal and oral (utilizing OROS technology) formulations of the established muscarinic antagonist, oxybutynin, for the treatment of urinary incontinence. The formulations are being developed to improve dosing and reduce side-effects associated with existing formulations of the drug.
openaire +2 more sources
Alza is developing both transdermal and oral (utilizing OROS technology) formulations of the established muscarinic antagonist, oxybutynin, for the treatment of urinary incontinence. The formulations are being developed to improve dosing and reduce side-effects associated with existing formulations of the drug.
openaire +2 more sources
Mapping the world of biomedical engineering: Alza lecture (1985)
Annals of Biomedical Engineering, 1986The key research areas of biomedical engineering are identified and analyzed. It is demonstrated how biomedical engineering fits into the world map of science. An analysis of biomedical engineering core journals provides statistical data about citation patterns in this discipline.
openaire +2 more sources
Bioelectric sources arising in excitable fibers (Alza lecture)
Annals of Biomedical Engineering, 1988This paper reviews the evaluation of bioelectric source strength and source field relationships for excitable fibers. For the single fiber, quantitative expressions describing the source may be derived which are independent of the fields produced by the sources.
openaire +2 more sources
1992 ALZA distinguished lecture: Bioengineering and vascular biology
Annals of Biomedical Engineering, 1994The vascular system is naturally dynamic; fluid mechanics and mass transfer are closely integrated with blood and vascular cell function. We are beginning to understand how local wall shear stress and strain modulate endothelial cell metabolism at the gene level.
openaire +2 more sources
Cybernetic limb prosthesis: The ALZA distinguished lecture
Annals of Biomedical Engineering, 1981The last two decades have witnessed a worldwide effort to provide limb amputees with prostheses which better emulate the natural control of the normal limb. The general schema is the detection of biopotentials indicative of centralnervous-system intent followed by timely and high-fidelity transfer of such signals to servomechanisms which mimic the ...
openaire +1 more source